司坦唑醇对血浆中快速纤溶酶原激活物抑制剂的调节作用。
Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol.
作者信息
Verheijen J H, Rijken D C, Chang G T, Preston F E, Kluft C
出版信息
Thromb Haemost. 1984 Jul 29;51(3):396-7.
PMID:6437007
Abstract
Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo.
摘要
口服司坦唑醇可提高血浆优球蛋白组分中的纤溶活性。这种提高并非由组织型纤溶酶原激活物的合成或释放增加所致。快速作用的组织型纤溶酶原激活物抑制水平降低很可能是活性升高的原因。这些结果表明，这种抑制在体内对纤溶具有调节作用。
Zotero 插件